Phase II data with ZD6474, a small-molecule kinase inhibitor of epidermal growth factor receptor and vascular endothelial growth factor receptor, in previously treated advanced non-small-cell lung cancer

被引:24
作者
不详
机构
关键词
D O I
10.1016/S1525-7304(11)70394-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
[No abstract available]
引用
收藏
页码:89 / 91
页数:3
相关论文
共 5 条
[1]   ZD6474 plus docetaxel in patients with previously treated NSCLC: Results of a randomized, placebo-controlled Phase II trial [J].
Herbst, R ;
Johnson, B ;
Rowbottom, J ;
Fidias, P ;
Lu, C ;
Prager, D ;
Roubec, J ;
Csada, E ;
Dimery, I ;
Heymach, J .
LUNG CANCER, 2005, 49 :S35-S36
[2]   Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors [J].
Holden, SN ;
Eckhardt, SG ;
Basser, R ;
de Boer, R ;
Rischin, D ;
Green, M ;
Rosenthal, MA ;
Wheeler, C ;
Barge, A ;
Hurwitz, HI .
ANNALS OF ONCOLOGY, 2005, 16 (08) :1391-1397
[3]  
MINAMI H, 2003, P AN M AM SOC CLIN, V22, P194
[4]   A comparison of the antitumour efficacy of ZD6474 and gefitinib (IresSa™) in patients with NSCLC:: Results of a randomized, double-blind Phase II study [J].
Natale, R ;
Bodkin, D ;
Govindan, R ;
Sleckman, B ;
Rizvi, N ;
Capo, A ;
Germonpré, P ;
Dimery, I ;
Webster, A ;
Ranson, M .
LUNG CANCER, 2005, 49 :S37-S37
[5]  
Wedge SR, 2002, CANCER RES, V62, P4645